Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03185325|
Recruitment Status : Not yet recruiting
First Posted : June 14, 2017
Last Update Posted : January 25, 2019
|Condition or disease||Intervention/treatment|
|Non Hodgkin Lymphoma||Other: bone marrow puncture and venous blood samples Other: venous blood samples|
Biomarkers are defined as objective indicators of biological processes, pathogenic processes, or pharmacological response to a therapeutic intervention. Diagnostic biomarkers which are type of biomarkers, identify the presence of disease, differentiate normal from malignant, distinguish different diagnoses or progression stages.
Micro ribosomal nucleic acids have been demonstrated to possess biomarker potentiality in multiple diseases, both individually and when combined in signature profiles. Micro ribosomal nucleic acids are short single-stranded noncoding ribosomal nucleic acids of 20-22 nucleotides that function to regulate gene expression at the posttranscriptional level. They play fundamental roles in the regulation of cellular proliferation, differentiation, and apoptosis. Dysregulation of micro ribosomal nucleic acid is a unique feature of cancers including lymphomas . Information about the functional role of micro ribosomal nucleic acid dysregulation in lymphomas is increasing day by day.
The present study focuses on the micro ribosomal nucleic acid 155 since this molecule represents a typical multifunctional micro ribosomal nucleic acid. To date, increased evidence points out that micro ribosomal nucleic acid 155 is involved in numerous biological processes including haematopoiesis, inflammation and immunity. Deregulation of micro ribosomal nucleic acid 155 has been found to be associated with different kinds of cancer, cardiovascular diseases and viral infections. Since investigation on the functional activity of micro ribosomal nucleic acid 155 started a few years ago, it is reasonable to predict that many other functions will be uncovered in the near future.
Micro ribosomal nucleic acid 155 maps within and is processed from an exon of a noncoding ribosomal nucleic acid transcribed from the B-cell Integration Cluster located on chromosome 21.
Micro ribosomal nucleic acid 155 is an oncological micro ribosomal nucleic acid with a crucial role in tumor initiation and development of several B-cell malignancies. Micro ribosomal nucleic acid 155 was upregulated in several malignancies compared to nonmalignant controls and overexpression of micro ribosomal nucleic acid 155 was further associated with poor prognosis. Elevated expression of micro ribosomal nucleic acid 155 shows potentiality as a diagnostic and prognostic biomarker in diffuse large B-cell lymphoma and chronic lymphocytic leukemia. Additionally, in vitro and in vivo studies suggest micro ribosomal nucleic acid 155 as an efficient therapeutic target, supporting its oncogenic function. The use of inhibiting anti-micro ribosomal nucleic acid structures indicates promising potential as novel anticancer therapeutics.
The search for non-invasive tools for the diagnosis and management of cancer has long been a goal of cancer research that has led to great interest in the field of circulating nucleic acids in plasma and serum.
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma|
|Estimated Study Start Date :||September 1, 2019|
|Estimated Primary Completion Date :||September 1, 2019|
|Estimated Study Completion Date :||December 1, 2019|
Non hodgkin lymphoma patients
bone marrow puncture and venous blood samples
Other: bone marrow puncture and venous blood samples
bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
venous blood samples
Other: venous blood samples
venous blood samples are collected in healthy voulnteers
- mean difference of micro ribosomal nucleic acid 155 expression levels between samples of both non hodgkin lymphoma patients and healthy controls [ Time Frame: 6 months ]measuring levels of micro ribosomal nucleic acid 155 in peripheral blood and bone marrow samples of non hodgkin lymphoma patients and in peripheral blood samples of healthy controls
- Mean difference of levels of expression of micro ribosomal nucleic acid 155 between peripheral blood and bone marrow samples of non hodgkin lymphoma patients [ Time Frame: 6 months ]measuring levels of expression of micro ribosomal nucleic acid 155 in peripheral blood and bone marrow samples in non hodgkin lymphoma patients
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03185325
|Contact: Hosny B Hamed, MDfirstname.lastname@example.org|
|Contact: Sahar M el-gammal, MD||00201002342312||Sahar.email@example.com|
|Principal Investigator:||Merna W Narouz||Assiut University|